U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
Publishing timestamp: 2023-12-07 09:14:26
Summary
The U.S. Food and Drug Administration is expected to approve the exa-cel gene-editing treatment for sickle cell disease, which would be the first approved medicine in the U.S. to use CRISPR gene-editing technology. The treatment, co-developed by Vertex Pharmaceuticals and CRISPR Therapeutics, aims to alleviate the symptoms of sickle cell disease by editing a person's DNA. The approval of exa-cel could be a breakthrough for patients and a scientific milestone, but it also presents a major test for the American healthcare system due to its high cost of around $2 million per patient.
Sentiment: POSITIVE
Keywords: business, science, bluebird bio inc, biotech and pharmaceuticals, crispr therapeutics ag, business news, united states, health care industry, vertex pharmaceuticals inc,
Source: https://www.cnbc.com/2023/12/07/crispr-gene-editing-treatment-us-approval.html